Genmab — November 2025

[npo]

My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.

[Bella1]

Tak, npo

[SEACOP]

Jeg nyder det høje niveau i dette forum, hvor jeg lærer meget. Det, som jeg ikke forstår, springer jeg nemt over. For mig findes kun dette sted, hvis jeg vil have god indsigt. Fortsæt venligst. Tak.

[lahn1]

Det koster blod, sved og tåre at være investeret i biotech. Jeg har sprugt meget i flere år Skriv en liste på alle de forkortelser og akronymer du har mødt, så er jeg sikker på de profesionelle her på PI er villige til at forklare. Det er min erfaring.

[E_L]

Pfizer Q3 2025 Tivdak $37mn , YTD $115mn . Now i don't know if this is the full number, as somewhere this year Genmab would assume more responsibilities for Tivdak / leading commercialization in Europe , so not sure who books what at the moment...

[Helge_LarsenPI-redaktør]

Knock-Your-Socks-Off-News – November 2025 https://www.linkedin.com/pulse/knock-your-socks-off-news-november-2025-genmab-vy0ze/

[E_L]

TEPEZZA
(teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter, driven by higher inventory levels and higher net selling price https://investors.amgen.com/news-releases/news-release-details/amgen-reports-third-quarter-2025-financial-results

[lahn1]

Har ikke noteret mig salget fra jnj og de øvrige partnere helt næøjagtigt, men vi ligger vel til en opjustering

[Raun]

Schyyyyy.... Opjusteringer er noget være lort for kursen

[JKY_VH]

Ser ud til at markedet regner med en solid opjustering. Aktien falder 2,4% pt.

[gdn55]

Novo nede med ca. 3,5 Ambu 18 Zeeland 3,5 Genmab 2,5.

[E_L]

Genmab A/S is set to announce its Q3 2025 earnings on November 6, 2025, with analysts expecting earnings of $0.47 per share and revenue of $975.4 million https://www.marketbeat.com/instant-alerts/genmab-as-gmab-expected-to-announce-quarterly-earnings-on-thursday-2025-10-30/

[E_L]

Genmab AS (GMAB, Financial) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $986.99 million, and the earnings are expected to come in at $0.46 per share. https://www.gurufocus.com/news/3185679/genmab-as-gmab-q3-2025-earnings-report-preview-what-to-look-for

[E_L]

seekingalpha: Genmab (GMAB) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. The consensus EPS Estimate is $0.45 and the consensus revenue estimate is $983.65M.

[Pensionisten]

Regnskab vel først efter markedet i DK er lukket - oplyst efter kl. 17.00 - som sædvanligt.

[Raun]

Flot dag i US - et luk lige i underkanten af 1900 under pæn omsætning

[bikube]

Da jeg så det, måtte jeg lige taste en gang mere på regneren - den siger 1897,4.

[transalp]

Go morgen..

[E_L]

so Novo confirmed yesterday they also submitted an appliction for approval of denecimig / Mim8 to EMA in september

[E_L]

From lab coat to Lifestar: Jan van de Winkel shares his success story
Before Genmab's co-founder and CEO collects his Lifetime Achievement Award this November, BioXconomy caught up with him for an exclusive chat about his remarkable journey. https://www.bioxconomy.com/partnering/from-lab-coat-to-lifestar-jan-van-de-winkel-shares-his-success-story